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a b s t r a c t
Skeletal muscle has been emerging as a research ﬁeld since the past 2 decades. Contrac-
tion of a muscle, which acts as a secretory organ, stimulates production, secretion, and
expression of cytokines or other muscle ﬁber-derived peptides, i.e., myokines. Exercise-
induced myokines inﬂuence crosstalk between different organs in an autocrine, endocrine,
or paracrine fashion. Myokines are recently recognized as potential candidates for treating
metabolic diseases through their ability to stimulateAMP-activatedprotein kinase signaling,
increase glucose uptake, and improve lipolysis. Myokines may have positive effects on
metabolic disorders, type 2 diabetes, or obesity. Numerous studies on myokines suggested
that myokines offer a potential treatment option for preventing metabolic diseases. This
review summarizes the current understanding of the positive effects of exercise-induced
myokines, such as interleukin-15, brain-derived neurotrophic factor, leukemia inhibitorymyokines factor, irisin, ﬁbroblast growth factor 21, and secreted protein acidic and rich in cysteine, on
metabolic diseases.
© 2014 Korea Institute of Oriental Medicine. Published by Elsevier. This is an open access
Exercise-induced beneﬁts are well known to prevent harm-1. Introduction
Many studies have demonstrated the beneﬁts of exercise in
preventing all-cause mortality, including cardiovascular dis-
ease, metabolic disease, and cancer.1–3 Exercise reduces the
risk of death by preventing metabolic diseases and protects
against chronic diseases. Organ-to-organ crosstalk involving
muscle contraction at themolecular level is emerging as a ﬁeld
4related to exercise. Additionally, adipokines are identiﬁed as
hormones that mediate crosstalk between adipose tissue and
brain, as well as metabolic functions during the activation
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of tissues.5 The proinﬂammatory role of various adipocyte-
produced adipokines has also been identiﬁed. Tumor necrosis
factor, chemokineC–Cmotif ligand 2, andplasminogen activa-
tor inhibitor-1 are proinﬂammatory adipokines that are overly
secreted in obesity, leading to metabolic and cardiovascular
diseases.6 Proinﬂammatory effects of these adipokines have
now been clearly recognized to be counterbalanced by the
protective effects of skeletal muscle-secreted peptides.4ute of Sports Science, Seoul National University, 599 Gwanak-ro,
ful effects of proinﬂammatory adipokines through skeletal
muscle-secreted proteins.4 A recent study by Pedersen et al.7
demonstrated the endocrine effects of muscle ﬁber-derived
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ytokines or peptides produced and secreted during skeletal
uscle contraction. The classiﬁed these cytokine andpeptides
s myokines. Furthermore, numerous studies demonstrated
hatmyokines are exercise induced.8–10 Themost well-known
xercise-induced myokine interleukin (IL)-6 was the ﬁrst
yokine to be identiﬁed in the bloodstream in response to
uscle contractions.11 IL-6 is a peptide that plays an anti-
nﬂammatory role by inhibiting tumor necrosis factor-; it also
mproves glucose uptake by stimulating AMP-activated pro-
ein kinase (AMPK) signaling.12–14 Surprisingly, circulating IL-6
evels are increasedduring exercisewithout any signofmuscle
amage.15
Myokines likely provide beneﬁcial metabolic effects dur-
ng crosstalk between skeletal muscle and liver, and skeletal
uscle and adipose tissue.16–18 Additionally, several studies
emonstrated that exercise-induced myokines have positive
ffects on glucose uptake,19,20 glucose tolerance,21 regula-
ion of fat oxidation,11,21 and satellite cell proliferation.22,23
yokines, as one of multiple health factors, constitute an
mportant area of research in metabolic diseases.24,25 This
eview summarizes the potential positive effects of exercise-
nduced myokines, such as IL-15, brain-derived neurotrophic
actor (BDNF), leukemia inhibitory factor (LIF), irisin, ﬁbroblast
rowth factor 21 (FGF-21), and secreted protein acidic and rich
n cysteine (SPARC), on metabolic diseases (Fig. 1 and Table 1).
. Interleukin-15
L-15 may play a role not only in muscle–fat interaction, but
lso in skeletal muscle ﬁber growth.26 IL-15, a member of the
L-2 superfamily, activates its functions through the  and 
hains of the IL-2 receptor.27,28 Quinn et al29 showed that IL-
5 can stimulate differentiated myocytes and muscle ﬁbers
o accumulate increased amounts of contractile proteins in
keletalmuscle. Additionally, IL-15 stimulatesmuscle-speciﬁc
yosin heavy-chain accumulation in differentiated myocytes
ndmuscle ﬁbers in culture.29,30 Among its various roles, IL-15
as been demonstrated to regulate metabolic diseases, such
s obesity and diabetes.21 IL-15 modulates glucose uptake in
ncubated skeletal muscle and muscle cell cultures.31 These
esults suggested that IL-15 may prevent the development of
iabetes.26 Busquets et al19 showed that in vivo administration
f IL-15 increased glucoseuptake in skeletalmuscle and in vitro
L-15 treatment increased glucose transporter type 4 mRNA
ontent in C2C12 cells. These ﬁndings indicate that IL-15 may
e an important mediator (regulator) of skeletal muscle ﬁber
rowth, hypertrophy, and glucose uptake.
Numerous studies demonstrated that exercise alters IL-
5 concentration in serum or at the mRNA level. The
ost noticeable change in serum IL-15 was observed after
oderate-intensity resistance training.32,33 Other studies
howed that aerobic training increased IL-15 in human and
odent serum and at the mRNA level.34,35 Given that IL-15
ontrols glucose and lipid metabolism, it may have an impor-
ant role in controlling metabolic diseases, including obesity
nd type 2 diabetes. However, studies on IL-15 expression
n the skeletal muscle and plasma after exercise showed
nconsistent results. It is evident that after resistance exer-
ise, IL-15 protein level increases in the plasma32,33; however,173
mRNA levels of IL-15 decrease after 2hours of intensive
strength training.36 In addition, circulating levels of IL-15were
increased in healthy young men, but remained unchanged
after a single bout of treadmill running.37 Treadmill exercise
increased IL-15 expression in the skeletal muscle of high-fat-
induced obese rats.35 Similar treadmill exercise conducted in
our laboratory showed an increase of IL-15 expression in the
soleusmuscle of a transgenic diabetic Zucker rat. Our data also
demonstrated that treadmill exercise improved glucose toler-
ance in the Zucker rat.38 In addition, 1 hour of acute exercise
increased IL-15 expression in Sprague–Dawley rats.39 These
data collectively suggest that exercise-induced IL-15 may be
important for themodulation of glucose uptake and improved
glucose tolerance.While the role of IL-15 in treatingmetabolic
diseases, such as obesity and type 2 diabetes, has now been
revealed, further investigation on changes in IL-15 and its
potential role is required.
3. Brain-derived neurotrophic factor
Neurotrophins are well-known regulators of various neuronal
processes and act primarily through tropomyosin-related
kinase receptor tyrosine kinases. The mammalian family of
neurotrophins consists of nerve growth factor, neurotrophin-
3, neurotrophin-4/5, and BDNF. Among these neurotrophins,
BDNF and its receptor tropomyosin-related kinase B are
most widely and abundantly expressed in the brain.40 To
date, numerous studies suggested that BDNF may play a
role not only in central metabolic pathways, but also as a
metabolic regulator of skeletal muscle. Wisse and Schwartz41
reported that BDNF is a key modulator of the hypothalamic
pathway that controls body composition and energy homeo-
stasis. BDNF is a regulator of metabolism in skeletal muscle42
and an enhancer of glucose utilization in diabetic skeletal
muscle.43 Current studies demonstrated that BDNF reduces
food intake and lowers blood glucose level in genetically
modiﬁed (db/db) obese mice, suggesting that BDNF plays a
role in energy balance and insulin signaling.44–46 In addi-
tion, a recent study suggested that gene transfer of BDNF
has therapeutic efﬁcacy in mouse models of obesity and
diabetes.47 It is now known that BDNF is expressed in non-
neurogenic tissues, including skeletal muscle. Animal studies
demonstrated that BDNF mRNA increases in skeletal mus-
cle in response to contraction.48,49 Numerous studies showed
that BDNF mRNA and protein expression were increased
in human skeletal muscle after exercise; however, skeletal
muscle-derived BDNF was not released into circulation.42
Additionally, BDNF increased phosphorylation of AMPK and
acetyl-CoA carboxylase-beta, and enhanced fat oxidation.
Based on recent research evidence, BDNF appears to be a
myokine that acts in an autocrine or paracrine fashion with
strong effects on peripheral metabolism, including fat oxida-
tion, and a subsequent effect on the size of adipose tissue.50
Skeletal muscle BDNF was reported as a key modulator in
metabolic diseases, including type 2 diabetes mellitus. In pre-
vious studies about diabetes and BDNF, increased BDNFmRNA
in the soleusmuscle of diabetic rats compared to age-matched
controls indicated that elevated BDNF may protect the dis-
tal nerve from the denervated muscle of diabetic rat.51,52 Our
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Fig. 1 – Potential role of exercise-induced myokines. Skeletal muscle expresses and releases myokines into the circulation.
Especially under conditions of metabolic diseases including obesity and diabetes, adipose tissue secretes proinﬂammatory
adipokines that promote pathological processes such as atherosclerosis and insulin resistance. However, exercise-induced
myokines may balance and counteract the effect of adipokines. In response to muscle contraction following exercise,
muscle ﬁbers express myokines such as irisin, IL-15, LIF, BDNF, FGF-21, and SPARC, which subsequently exert their effects
locally within the muscle or their target organs.
AMPK, AMP-activated protein kinase; BDNF, brain-derived neurotrophic factor; FGF-21, ﬁbroblast growth factor 21; IL,
protinterleukin; LIF, leukemia inhibitory factor; SPARC, secreted
unpublished data also showed an increased BDNF expression
in the soleus muscle of type 2 diabetes mellitus-induced rats
as compared to the lean controls. We also found signiﬁcant
decreases in BDNF expression following resistance exercise
in the soleus, tibialis anterior, and extensor digitorum longus
muscles. BDNF in skeletal muscle may be expressed as a com-
pensatory neurotrophic factor against diabetic neuropathy or
myopathy.
Although the important role of BDNF in peripheral
metabolism including skeletal muscle metabolism is well
known, the role of BDNF expression in diabetic skeletalmuscle
with severe glucose tolerance is not fully established. More-
over, considering the role of BDNF in skeletal muscle, further
research is required to investigate the effect of physical exer-
cise and nutritional treatment on BDNF expression and its
potential to improved glucose metabolism in diabetic skeletal
muscle.
4. Leukemia inhibitory factor
LIF is known as an important player in skeletal muscle
hypertrophy and regeneration by enhancing cell proliferation
though the common signaling mediators janus kinase (JAK),
signal transducer and activator of transcription-3 (STAT3), and
phosphoinositide-3-kinase.53–56 Previous studies showed that
LIF mRNA is upregulated exogenously after muscle injury,ein acidic and rich in cysteine; UCP-1, uncoupling protein 1.
including muscle crush and contusion injury.57 LIF is a newly
discovered myokine23; it is produced by skeletal muscle and
affects intact muscles, as well as isolated muscle cells.58,59
Among its various roles, themost important role of LIF inmus-
cle satellite cell is proliferation for proper muscle hypertrophy
and regeneration.23
Although studies on exercise-related LIF expression
remained controversial, LIF mRNA levels increased after a
single bout of both cycle ergometer exercise58 and heavy
resistance exercise59 in the human vastus lateralis muscle,
whereas LIF protein levels were not signiﬁcantly changed.
Since LIF has a very short half-life of 6–8minutes in serum,
it is difﬁcult to detect circulating levels of LIF protein.60 More-
over, LIF promotes survival ofmyoblasts in dystrophicmuscle;
however, LIF mRNA levels were found to decrease after 2
weeks of voluntary wheel running in mdx mice.61 Numerous
studies demonstrated that LIF clearly has the potential to reg-
ulate skeletal muscle disease, including muscular dystrophy,
and it furthermore promotes myoblast survival in dys-
trophic muscle.61 These studies suggested that LIF provides
alternative therapeutic ways to stimulate skeletal muscle
regeneration in an autocrine or paracrine fashion after injury.
However, the duration of increased LIF mRNA and protein lev-
els after exercise is not well known. Further investigation is
needed to describe the relationships between alteration of LIF
mRNA, and protein levels and exercise duration or type.
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Table 1 – Studies of exercise-induced myokines
Myokine Subjects Exercise Results Refs
IL-15 Human Treadmill running
(70% maximum heart rate, 30 min)
Serum IL-15 level ↑ 34
Rat Treadmill running
(26 m/min, 60min each, 5 d/wk for 8 wk)
IL-15 mRNA (in muscle) ↑
IL-15 Receptor ↑




(4 sets, 10 repetitions, 2–3min rest
intervals)




(3 d/wk, 75% of one repetition maximum,
6–10 repetitions)
Plasma IL-15 level ↑
IL-15 receptor- gene ↑
32
Rat Treadmill exercise













BDNF Rat Treadmill exercise






(2–30 d acute exercise)
BDNF mRNA ↑ 49
Human Bicycle exercise








LIF Human Cycle ergometer exercise
(3 h, VO2 max 60%)
LIF mRNA↑
(increased 4.5-fold after exercise)
58
Human Resistance exercise
(a bout of heavy resistance exercise)
LIF mRNA↑
(increased 9-fold after exercise)
59





Irisin Mice Voluntary wheel running
(free wheel running, 3 wk)
Plasma irisin level ↑ 63
Human Endurance exercise
(cycle, VO2 max 65%, 4–5 sessions/10 wk)
Plasma irisin level ↑
Human Acute exercise
(80 m spirit runs, 3 d/1 wk)
Serum irisin level ↑ 67
FGF-21 Human Treadmill exercise
(the Bruce’s protocol 5 d/2 wk, 21 min)
Serum FGF-21 level ↑ 75
Human Acute exercise




(a single bout of treadmill exercise, 30min
or until exhaustion)
SPARC Human Acute exercise
(a single bout of cycling, VO2 max 70%, 30
min)




(VO2 max 70%; 2, 4 weeks)







tACC, acetyl-CoA carboxylase-beta; AMPK, AMP-activated protein k
factor 21; IL, interleukin; LIF, leukemia inhibitory factor; NT-3, neurot
. Irisinrisin is a peroxisome proliferator-activated receptor-
oactivator-1 (PPAR-) coactivator-1  (PGC1-)-dependent
yokine, and seems to be capable of inducing white adipose
issue browning and uncoupling protein 1 expression.62; BDNF, brain-derived neurotropic factor; FGF-21, ﬁbroblast growth
n-3; SPARC, secreted protein acidic and rich in cysteine.
PGC-1 is best known to regulate energy metabolism; how-
ever, it has other beneﬁcial actions, such as control of
mitochondrial biogenesis and oxidative metabolism in many
63cell types. PGC-1 is induced in muscles by exercise and
stimulates mitochondrial biogenesis, angiogenesis, and
ﬁber-type switching.64 PGC-1 stimulates the expression
of ﬁbronectin type III domain-containing protein 5 (FNDC5)
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gene that encodes irisin, a type I membrane protein secreted
into the blood. Irisin activates profound changes in the
subcutaneous adipose tissue by stimulating browning and
uncoupling protein 1 expression.63
Recent research indicated that, in an obese rodent model,
FNDC5 treatment improved glucose tolerance and elevated
expression of mitochondrial genes that increase oxygen
consumption.63,65 Exercise may increase plasma irisin lev-
els. Results from several studies suggested that plasma
irisin levels were elevated in rodents and humans following
exercise.63,66,67 Bostrom et al63 demonstrated an increase of
plasma irisin level in mice after 3 weeks of voluntary wheel
running, and a twofold increase of circulating plasma irisin
level in healthy adults compared to the nontraining group
after 10 weeks of endurance exercise. In addition, irisin levels
increased in response to acute exercise.63 Our recent labo-
ratory data on 8 weeks of aerobic exercise and resistance
exercise in obese humans demonstrated a positive correla-
tion between the circulating irisin level and changes ofmuscle
mass, and a negative correlation between the circulating irisin
level and changes of fat mass and body fat percentage.67
Despite differences in results, both previous studies and our
study consistently demonstrated an increased level of irisin
following exercise.66 Therefore, irisin has potential as a ther-
apeutic agent. Further study is required to investigate the
changes in irisin levels and its protective role in obesity and
diabetes following exercise.
6. Fibroblast growth factor 21
FGF-21, an endocrine hormone, plays an important role in the
progression ofmetabolic regulation by controlling glucose and
lipid metabolism.68–70 FGF-21 is expressed in peripheral tis-
sues, such aswhite adipose tissue, liver, pancreas, and skeletal
muscle.71 FGF-21 levels increased during starvation and the
ketogenic state, and decreased after refeeding.72 Administra-
tion of FGF-21 reduced plasma glucose and triglycerides, and
increased insulin sensitivity in diabetic rodents.73 Walsh and
coworkers74 also demonstrated that FGF-21 is produced by
skeletal muscle. Several studies determine FGF-21 as a key
factor for downstream target of PPAR-. FGF-21 may thus
play an important role in metabolism. Recent studies sug-
gested that FGF-21 levels were elevated in metabolic diseases,
including insulin resistance, metabolic syndrome, and type 2
diabetes. Hojman et al’s70 study demonstrated an increased
FGF-21 expression inmuscle andplasma in response to insulin
stimulation. Additionally, FGF-21-null mice not only failed to
express PGC-1, but also had impaired gluconeogenesis and
ketogenesis.
Recent studies showed that FGF-21 is elevated after exer-
cise. In healthy humans, serum FGF-21 levels increased after
2 weeks of treadmill exercise.75 Serum FGF-21 levels also
increased in mice and humans by a single bout of acute
exercise.76 The increase in FGF-21 was accompanied by an
increase in lipolytic response, leading to the release of free
fatty acid and glycerol. Data of these studies might have sug-
gested that increased serum FGF-21 levels lead to increased
lipolysis and decreased glucose levels after a high-intensity
exercise.75,76 According to our unpublished data, 8 weeks ofIntegr Med Res ( 2 0 1 4 ) 172–179
ladder climbing exercise increased FGF-21 level in the soleus
and extensor digitorum longus muscles in type 2 diabetes
rats. FGF-21 might be elevated in response to exercise, greatly
affecting metabolic mechanisms. Therefore, further study is
required to investigate changes in the FGF-21 level in response
to the duration or type of exercise, for effective treatment of
diabetes.
7. Secreted protein acidic and rich in
cysteine
SPARC, also known as BM-40 was initially identiﬁed in bone
and hence was named osteonectin initially.77 For a decade,
intense studies on the effect of SPARC on various patho-
logical conditions of organs such as the liver and kidney
were conducted.78 SPARC acts as a counteradhesive and a
modulator of cell–surface interaction during tissue renewal
and remodeling, which requires regulation of cell–matrix
or cell–cell contact.79 Most studies on regulation of SPARC
expression and function are related to bone. During osteo-
genesis, SPARC links the organic and mineral phases of the
bone extracellular matrix.80 However, recent studies revealed
that SPARC is also found in myoblasts, myotubes, and muscle
ﬁbers, where its levels increase during muscle development
and regeneration.81 Importantly, SPARC secretion was found
to increase in muscles not only during regeneration, but
also following resistance exercise and muscle hypertrophy.82
A single bout of exercise increases secretion of SPARC in
mice. Levels of SPARC in the gastrocnemius muscle were
signiﬁcantly increased after a single bout of exercise, specif-
ically around the plasma membrane. However, SPARC levels
decreased immediately after exercise. In addition, SPARC was
increased in the serum of young healthy men immediately
after a single bout of cycling at 70% VO2 max for 30minutes,
but gradually decreased to the resting level. However, 4 weeks
of training at 70% VO2 max resulted in a signiﬁcant increase
in serum SPARC, with no changes in the resting state.83
SPARC is currently identiﬁed as one of the myokines
that reduces fat accumulation and is involved in glucose
metabolism.84,85 First, SPARC is involved in the regulation
of adipocyte differentiation and adipose tissue turnover84 by
activating the Wnt/-caternin pathway that inhibits adipo-
genesis and enhances osteoblastogenesis.86–88 In addition,
SPARC, by having a dose-dependent inhibitory effect on adi-
pogenesis and formation of osteoblast, was also enhanced
in a dose-dependent fashion. Primary culture of SPARC-null
mice cells showed increased adipocyte and fat accumulation
as compared to wild-type mice.84 SPARC decreased adipogen-
esis by regulating expression, deposition, and organization
of extracellular matrix protein rather than by interfering
adipogenesis directly. It modulates monoclonal anticellular
ﬁbronectin and antimouse laminin production in the extracel-
lular matrix during adipogenesis, where ﬁbronectin inhibits
adipogenesis and laminin enhances adipogenesis.84 These
changes inhibit the rearrangement of F-actin and stress ﬁbers
form the ﬁber-like preadipocyte cell structure, which weak-
ens during adipogenesis to allow fat accumulation.84 SPARC
is also involved in glucosemetabolism via the AMPK signaling
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n energy-sensing pathway that plays a critical role in regu-
ating glucose and fat metabolism in skeletal muscle during
xercise.89,90 It stimulates glucose uptake by increasing glu-
ose transporter translocation.91,92 Further study is needed to
nvestigate the change in SPARC level according to the exercise
uration, to effectively regulate glucose and fat metabolism.
. Conclusion
mall changes induced by exercise can create a ripple effect
f beneﬁts to the entire body. It is well known that exer-
ise satisﬁes essential requirements for a healthy life. Regular
hysical activity or exercise can prevent chronic diseases,
uch as cardiovascular diseases, metabolic diseases, and cog-
itive disorders. Findings from previous studies indicated that
xercise-induced myokines might be the potential candidates
o provide beneﬁcial effects by stimulating metabolic path-
ays, improving glucose uptake, improving fat oxidation, and
egulating skeletal muscle regeneration. Based on a review
f the literature, we provide new insights into the role of
xercise-induced myokines as important potential therapeu-
ic factors for the prevention of metabolic diseases. Further
esearch is clearly required to identify how exercise-induced
yokines relate to chronic or metabolic diseases, including
ype 2 diabetes, obesity, and muscle atrophy.
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